OS Therapies’ OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers
OS Therapies (NYSE-A: OSTX) announced its immunotherapy treatment OST-HER2 will be featured in the documentary 'Shelter Me: The Cancer Pioneers', focusing on canine comparative oncology. The film explores the similarities between cancer treatments in dogs and humans, particularly for rare cancers.
OST-HER2 is an experimental immunotherapy for osteosarcoma that uses a bioengineered form of Listeria monocytogenes bacteria targeting HER2-expressing cancer cells. The documentary highlights the 96% genetic similarity between human and canine osteosarcoma, underlining the importance of comparative oncology research.
The film will premiere at AMC Century City in Los Angeles on April 3, 2025, followed by streaming availability on PBS platforms in May. The documentary features scientists from various institutions including the National Cancer Institute, University of Pennsylvania, University of Illinois, University of Wisconsin, and Colorado State University.
OS Therapies (NYSE-A: OSTX) ha annunciato che il suo trattamento immunoterapico OST-HER2 sarà presentato nel documentario 'Shelter Me: The Cancer Pioneers', che si concentra sull'oncologia comparativa canina. Il film esplora le somiglianze tra i trattamenti per il cancro nei cani e negli esseri umani, in particolare per i tumori rari.
OST-HER2 è un'immunoterapia sperimentale per osteosarcoma che utilizza una forma bioingegnerizzata di batteri Listeria monocytogenes mirata alle cellule tumorali che esprimono HER2. Il documentario evidenzia il 96% di somiglianza genetica tra l'osteosarcoma umano e quello canino, sottolineando l'importanza della ricerca in oncologia comparativa.
Il film avrà la sua prima al AMC Century City di Los Angeles il 3 aprile 2025, seguito dalla disponibilità in streaming sulle piattaforme PBS a maggio. Il documentario presenta scienziati di varie istituzioni, tra cui il National Cancer Institute, l'Università della Pennsylvania, l'Università dell'Illinois, l'Università del Wisconsin e la Colorado State University.
OS Therapies (NYSE-A: OSTX) anunció que su tratamiento de inmunoterapia OST-HER2 será presentado en el documental 'Shelter Me: The Cancer Pioneers', que se centra en la oncología comparativa canina. La película explora las similitudes entre los tratamientos del cáncer en perros y humanos, especialmente para los cánceres raros.
OST-HER2 es una inmunoterapia experimental para osteosarcoma que utiliza una forma bioingenierizada de la bacteria Listeria monocytogenes dirigida a las células cancerosas que expresan HER2. El documental destaca el 96% de similitud genética entre el osteosarcoma humano y canino, subrayando la importancia de la investigación en oncología comparativa.
La película se estrenará en AMC Century City en Los Ángeles el 3 de abril de 2025, seguida de la disponibilidad en streaming en las plataformas de PBS en mayo. El documental presenta a científicos de diversas instituciones, incluyendo el National Cancer Institute, la Universidad de Pensilvania, la Universidad de Illinois, la Universidad de Wisconsin y la Universidad Estatal de Colorado.
OS Therapies (NYSE-A: OSTX)는 면역 요법 치료제 OST-HER2가 개의 비교 종양학에 초점을 맞춘 다큐멘터리 'Shelter Me: The Cancer Pioneers'에 소개될 것이라고 발표했습니다. 이 영화는 개와 인간의 암 치료 방법 간의 유사성을 탐구하며, 특히 희귀 암에 대해 다룹니다.
OST-HER2는 골육종에 대한 실험적인 면역 요법으로, HER2를 발현하는 암세포를 표적으로 하는 생물공학적 형태의 리스테리아 모노사이토제네스 박테리아를 사용합니다. 다큐멘터리는 인간과 개의 골육종 간의 96% 유전적 유사성을 강조하며, 비교 종양학 연구의 중요성을 부각시킵니다.
이 영화는 2025년 4월 3일 로스앤젤레스의 AMC 센추리 시티에서 초연되며, 5월에는 PBS 플랫폼에서 스트리밍 가능해질 예정입니다. 이 다큐멘터리는 국립암연구소, 펜실베이니아 대학교, 일리노이 대학교, 위스콘신 대학교, 콜로라도 주립대학교 등 다양한 기관의 과학자들을 특징으로 하고 있습니다.
OS Therapies (NYSE-A: OSTX) a annoncé que son traitement d'immunothérapie OST-HER2 sera présenté dans le documentaire 'Shelter Me: The Cancer Pioneers', qui se concentre sur l'oncologie comparative canine. Le film explore les similitudes entre les traitements du cancer chez les chiens et chez les humains, en particulier pour les cancers rares.
OST-HER2 est une immunothérapie expérimentale pour ostéosarcome qui utilise une forme bio-ingénierie de la bactérie Listeria monocytogenes ciblant les cellules cancéreuses exprimant HER2. Le documentaire met en évidence la similitude génétique de 96 % entre l'ostéosarcome humain et canin, soulignant l'importance de la recherche en oncologie comparative.
Le film sera présenté en première au AMC Century City à Los Angeles le 3 avril 2025, suivi d'une disponibilité en streaming sur les plateformes PBS en mai. Le documentaire présente des scientifiques de diverses institutions, y compris le National Cancer Institute, l'Université de Pennsylvanie, l'Université de l'Illinois, l'Université du Wisconsin et l'Université d'État du Colorado.
OS Therapies (NYSE-A: OSTX) gab bekannt, dass ihre Immuntherapie OST-HER2 im Dokumentarfilm 'Shelter Me: The Cancer Pioneers' vorgestellt wird, der sich auf die vergleichende Onkologie bei Hunden konzentriert. Der Film untersucht die Ähnlichkeiten zwischen Krebsbehandlungen bei Hunden und Menschen, insbesondere bei seltenen Krebserkrankungen.
OST-HER2 ist eine experimentelle Immuntherapie gegen Osteosarkom, die eine bioengineered Form von Listeria monocytogenes-Bakterien verwendet, um HER2-exprimierende Krebszellen anzugreifen. Der Dokumentarfilm hebt die 96% genetische Ähnlichkeit zwischen menschlichem und canine Osteosarkom hervor und unterstreicht die Bedeutung der vergleichenden Onkologie-Forschung.
Der Film feiert seine Premiere am 3. April 2025 im AMC Century City in Los Angeles, gefolgt von einer Streaming-Verfügbarkeit auf PBS-Plattformen im Mai. Der Dokumentarfilm zeigt Wissenschaftler verschiedener Institutionen, darunter das National Cancer Institute, die Universität von Pennsylvania, die Universität von Illinois, die Universität von Wisconsin und die Colorado State University.
- Company's experimental cancer treatment OST-HER2 gains visibility through PBS documentary exposure
- Strong scientific basis with 96% genetic similarity between human and canine osteosarcoma supporting research approach
- OST-HER2 is still an investigational drug not approved for any treatment
- No clinical efficacy or safety data presented in the announcement
Documentary focusing on canine comparative oncology will premiere at the Los Angeles AMC Century City on April 3rd
“Our team is dedicated to advancing a treatment for osteosarcoma and are proud to see our immunotherapy in Shelter Me: The Cancer Pioneers,” stated OS Therapies’ CEO Paul Romness. “Comparative oncology is an important area of research for us because of the striking genetic homology of over
Shelter Me: The Cancer Pioneers also features leading scientists at the National Cancer Institute / National Institutes of Health, the University of
A trailer of the movie can be viewed here.
About OS Therapies
OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the US Food & Drug Administration and Fast-Track and Orphan Drug designations from the US FDA and European Medicines Agency. The Company positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a Biologics Licensing Application (BLA) to the US FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the
In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the US FDA and grant of a priority review voucher and other risks and uncertainties described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s registration statement on Form S-1 filed with the Securities and Exchange Commission (the “SEC”) on November 12, 2024, as amended on November 27, 2024, and other subsequent documents we file with the SEC, including but not limited to our Quarterly Reports on Form 10-Q. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250325194230/en/
OS Therapies Contact Information:
Jack Doll
571.243.9455
Irpr@ostherapies.com
https://x.com/OSTherapies
https://www.instagram.com/ostherapies/
https://www.facebook.com/OSTherapies/
https://www.linkedin.com/company/os-therapies/
Source: OS Therapies
FAQ
What is OST-HER2 and how does it work against osteosarcoma (OSTX)?
When will the documentary featuring OSTX's cancer treatment be available for streaming?
What is the significance of comparative oncology for OSTX's osteosarcoma treatment?
Which research institutions are featured alongside OSTX in the Cancer Pioneers documentary?
